Affiliation:
1. University Health Systems—Primary Care and Medical College of Georgia, Augusta University, Augusta, GA
Abstract
In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypoglycemia. This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference43 articles.
1. Mechanisms of pancreatic secretion;Bayless;J Physiol (Lond),1902
2. On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane;Moore;Biochem J,1906
3. Contributions a l’etude des variations physiologiques entre des la secretion intune du pancreas: relations entre les secretions externe et interne du pancreas;Zunz;Arch Int Physiol Biochem,1929
4. Studies on the physiology of secretin;LaBarre;Am J Physiol,1930
5. Is a duodenal hormone involved in carbohydrate metabolism?;Loew;Am J Physiol,1940
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献